Subcutaneous Reccurent Myxoid Liposarcoma

Abstract

Subkutan Nükseden Miksoid Liposarkom

Öz

Liposarcoma, one of the most common soft-tissue sarcomas, originates from primitive mesenchymal cells, and its diagnostic have been well established.  Myxoid liposarcoma is the second most common histological subtype, occurring more frequently during the fourth and fifth decades of life.

We describe a case of recurrent myxoid liposarcoma of the right flank in 50 years old man. Treatment of the recurrence  involved chemotherapy neo-adjuvant (3 courses), wide surgical resection (resection R1) followed by locoregional radiation therapy. Patient’s evolution was marked by complete remission maintained after 12 months follow-up.

The myxoid liposarcoma has a low rate of local failure with trimodality therapy combined chemotherapy, radiotherapy and surgery.

Anahtar Kelimeler

• Myxoid liposarcoma (MLS),recurrence,chemotherapy,radiotherapy

References

1. 1. Antonescu C., Ladanyi M. Myxoid liposarcoma. In: Fletcher C. D. M., Unni K. K., Mertens F., editors. World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of Soft Tissue and Bone. Lyon, France: IARC Press; 2002. pp. 40–43.2. de Vreeze R. S. A., de Jong D., Haas R. L., Stewart F., van Coevorden F. Effectiveness of radiotherapy in myxoid sarcomas is associated with a dense vascular pattern. International Journal of Radiation Oncology, Biology, Physics. 2008;72(5):1480–1487. doi: 10.1016/j.ijrobp.2008.03.008. 3. Jones R. L., Fisher C., Al-Muderis O., Judson I. R. Differential sensitivity of liposarcoma subtypes to chemotherapy. European Journal of Cancer. 2005;41(18):2853–2860. doi: 10.1016/j.ejca.2005.07.023. 4. Crago AM, Dickson MA. Liposarcoma: multimodality management and future targeted therapies. Surg Oncol Clin N Am. 2016;25(4):761–73. https://doi.org/10. 1016/j.soc.2016.05.007.5. Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196(3):305–15.6. Trovik CS, Bauer HC, Alvegard TA, Anderson H, Blomqvist C, Berlin O, et al. Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. Eur J Cancer. 2000;36(6):710–6.7. Gronchi A, Casali PG, Mariani L, Miceli R, Fiore M, Lo Vullo S, et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. J Clin Oncol. 2005;23(1):96–104. https://doi.org/10.1200/JCO. 2005.04.160.8. Chung PW, Deheshi BM, Ferguson PC, Wunder JS, Griffin AM, Catton CN, et al. Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas. Cancer. 2009;115(14):3254–61. https://doi. org/10.1002/cncr.24375.9. Cheng EY, Dusenbery KE, Winters MR, Thompson RC. Soft tissue sarcomas: preoperative versus postoperative radiotherapy. J Surg Oncol. 1996;61(2):90–9. https:// doi.org/10.1002/(SICI)1096-9098(199602) 61:2G90::AID-JSO293.0.CO;2-M.10. Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized Curr. Treat. Options in Oncol. (2018) 19:64 Page 11 of 13 64 cooperative trial. J Clin Oncol. 2001;19(5):1238–47. https://doi.org/10.1200/JCO.2001.19.5.1238.11. Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18(6):812–22. https://doi.org/10.1016/S1470- 2045(17)30334-0.